Search Results Search Sort by RelevanceMost Recent Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063. Case and Commentary Sep 2021 How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices? Beatrice L. Brown, MBE and Aaron S. Kesselheim, MD, JD, MPH Heightened caution, improved physician and patient communication, and equitable access are key priorities. AMA J Ethics. 2021;23(9):E673-678. doi: 10.1001/amajethics.2021.673. Medical Education Sep 2021 What Should the Public Know About Implantable Material and Device Innovation in the US? Donna-Bea Tillman, PhD, MPA Device innovation has potential to improve patient outcomes over time, yet prospective benefits must be considered in light of risks. AMA J Ethics. 2021;23(9):E697-701. doi: 10.1001/amajethics.2021.697. Case and Commentary Aug 2023 Should Organizational Investment in Robotic Surgical Technology Ever Influence Surgeons’ Decisions About Surgical Approach to Patients’ Surgical Care? Ryan D. Rosen, DO and David A. Edelman, MD, MSHPEd Costs partly determine organizational robotics, but questions remain about whether and to what extent they should influence care decisions. AMA J Ethics. 2023;25(8):E575-582. doi: 10.1001/amajethics.2023.575. Case and Commentary Aug 2023 How Should Risk Be Communicated to Patients When Developing Resident Surgeon Robotic Skills? Matthew C. Bobel, MD and Robert K. Cleary, MD This article suggests strategies for how to disclose the nature and scope of resident surgeon involvement in managing intraoperative care. AMA J Ethics. 2023;25(8):E583-588. doi: 10.1001/amajethics.2023.583.
Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063.
Case and Commentary Sep 2021 How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices? Beatrice L. Brown, MBE and Aaron S. Kesselheim, MD, JD, MPH Heightened caution, improved physician and patient communication, and equitable access are key priorities. AMA J Ethics. 2021;23(9):E673-678. doi: 10.1001/amajethics.2021.673.
Medical Education Sep 2021 What Should the Public Know About Implantable Material and Device Innovation in the US? Donna-Bea Tillman, PhD, MPA Device innovation has potential to improve patient outcomes over time, yet prospective benefits must be considered in light of risks. AMA J Ethics. 2021;23(9):E697-701. doi: 10.1001/amajethics.2021.697.
Case and Commentary Aug 2023 Should Organizational Investment in Robotic Surgical Technology Ever Influence Surgeons’ Decisions About Surgical Approach to Patients’ Surgical Care? Ryan D. Rosen, DO and David A. Edelman, MD, MSHPEd Costs partly determine organizational robotics, but questions remain about whether and to what extent they should influence care decisions. AMA J Ethics. 2023;25(8):E575-582. doi: 10.1001/amajethics.2023.575.
Case and Commentary Aug 2023 How Should Risk Be Communicated to Patients When Developing Resident Surgeon Robotic Skills? Matthew C. Bobel, MD and Robert K. Cleary, MD This article suggests strategies for how to disclose the nature and scope of resident surgeon involvement in managing intraoperative care. AMA J Ethics. 2023;25(8):E583-588. doi: 10.1001/amajethics.2023.583.